脓毒症/血管麻痹性休克患者使用CytoSorb血液吸附辅助治疗:最佳实践共识声明
危重症患者因感染或非感染因素出现宿主反应失调,释放大量炎症介质形成「细胞因子风暴」,目前尚无获批疗法调节过度免疫反应。体外血液净化通过广谱非选择性清除炎症介质受到关注,CytoSorb®血液吸附装置在多种原因所致高炎症患者中显示初步前景。该综述讨论现有证据,并提供CytoSorb®血液吸附用于血管麻痹性休克患者的共识性最佳实践指导。患者选择、治疗启动时机、吸附器更换方案和疗程、以及对抗生素等药物清除的潜在影响仍是待研究问题。
要点
- 危重症患者宿主反应失调可导致危及生命的器官功能障碍,仍是全球ICU主要死亡原因。
- 目前尚无获批疗法调节过度免疫反应、限制高炎症以预防相关器官衰竭和死亡。
- CytoSorb®血液吸附装置在多种原因所致高炎症患者中显示有前景的结果。
- 患者选择、启动时机、吸附器更换方案和疗程、以及对抗生素等合并用药的潜在清除仍是待研究问题。
- 该共识为血管麻痹性休克患者使用CytoSorb®血液吸附提供基于共识的最佳实践指导。
适用人群与场景
- 血管麻痹性休克患者
- 高炎症(细胞因子风暴)患者,可源于感染或非感染因素
研究设计与关键结果
- 该综述讨论现有证据并提供CytoSorb®血液吸附治疗血管麻痹性休克的共识性最佳实践指导。
- CytoSorb®血液吸附装置在多种原因所致高炎症患者中显示有前景的结果。
证据类型、等级与局限
- 证据类型:共识声明(基于现有证据的综述与共识性最佳实践指导)。
- 局限:患者选择、治疗启动时机、吸附器更换方案和疗程、以及对抗生素等合并用药的潜在清除等关键问题仍待研究。
对床旁实践的改变
- 该共识为血管麻痹性休克患者使用CytoSorb®血液吸附提供基于共识的最佳实践指导。
指南或共识出处
- Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement(J Clin Med)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
A dysregulated host response is a common feature in critically ill patients due to both infectious and non-infectious origins that can lead to life-threatening organ dysfunction, which is still the primary cause of death in intensive care units worldwide. In its course, pathologic, unregulated levels of inflammatory mediators are often released into the circulation, a phenomenon also referred to as a "cytokine storm". To date, there are no approved therapies to modulate the excessive immune response and limit hyperinflammation with the goal of preventing related organ failure and death. In this context, extracorporeal blood purification therapies aiming at the alteration of the host inflammatory response through broad-spectrum, non-selective removal of inflammatory mediators have come into focus. A novel hemoadsorption device (CytoSorb®, CytoSorbents Inc., Princeton, NJ, USA) has shown promising results in patients with hyperinflammation from various origins. Although a significant body of literature exists, there is ongoing research to address many important remaining questions, including the optimal selection of patient groups who might benefit the most, optimal timing for therapy initiation, optimal schedule for adsorber exchanges and therapy duration, as well as an investigation into the potential removal of concomitant antibiotics and other medications. In this review, we discuss the existing evidence and provide a consensus-based best practice guidance for CytoSorb® hemoadsorption therapy in patients with vasoplegic shock.
参考来源
- Mitzner S, Kogelmann K, Ince C, et al. Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus Statement. J Clin Med. 2023. PMID: 38068250. doi:10.3390/jcm12237199
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。